Source Name	Characteristics[organism]	Characteristics[organism part]	Characteristics[pool]	Characteristics[age]	Characteristics[developmental stage]	Characteristics[ancestry category]	Characteristics[cell line]	Characteristics[cell type]	Characteristics[sex]	Characteristics[disease]	Characteristics[depletion]	Characteristics[individual]	Material Type	assay name	Technology Type	comment[fractionation method]	comment[fraction identifier]	comment[file uri]	comment[instrument]	comment[separation]	comment[label]	comment[cleavage agent details]	comment[modification parameters]	comment[dissociation method]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	comment[data file]	Factor value[pool]
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 1	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx01.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 2	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx01.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 3	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx01.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 4	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx01.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 5	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx01.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 6	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx01.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 7	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx02.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 8	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx02.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 9	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx02.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 10	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx02.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 11	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx02.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 12	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx02.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 13	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx03.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 14	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx03.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 15	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx03.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 16	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx03.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 17	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx03.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 18	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx03.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 19	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx04.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 20	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx04.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 21	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx04.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 22	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx04.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 23	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx04.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 24	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx04.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 25	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx05.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 26	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx05.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 27	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx05.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 28	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx05.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 29	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx05.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 30	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx05.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 31	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx06.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 32	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx06.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 33	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx06.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 34	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx06.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 35	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx06.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 36	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx06.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 37	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx07.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 38	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx07.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 39	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx07.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 40	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx07.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 41	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx07.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 42	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx07.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 43	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx08.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 44	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx08.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 45	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx08.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 46	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx08.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 47	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx08.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 48	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx08.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 49	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx09.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 50	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx09.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 51	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx09.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 52	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx09.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 53	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx09.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 54	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx09.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 55	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx10.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 56	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx10.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 57	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx10.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 58	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx10.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 59	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx10.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 60	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx10.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 61	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx11.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 62	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx11.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 63	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx11.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 64	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx11.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 65	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx11.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 66	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx11.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 67	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx12.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 68	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx12.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 69	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx12.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 70	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx12.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 71	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx12.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 72	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx12.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 73	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx13.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 74	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx13.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 75	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx13.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 76	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx13.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 77	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx13.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 78	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx13.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 79	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx14.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 80	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx14.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 81	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx14.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 82	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx14.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 83	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx14.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 84	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx14.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 85	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx15.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 86	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx15.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 87	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx15.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 88	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx15.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 89	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx15.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 90	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx15.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 91	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx16.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 92	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx16.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 93	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx16.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 94	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx16.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 95	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx16.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 96	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx16.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 97	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx17.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 98	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx17.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 99	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx17.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 100	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx17.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 101	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx17.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 102	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx17.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 103	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx18.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 104	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx18.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 105	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx18.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 106	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx18.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 107	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx18.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 108	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx18.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 109	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx19.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 110	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx19.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 111	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx19.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 112	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx19.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 113	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx19.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 114	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx19.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 115	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx20.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 116	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx20.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 117	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx20.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 118	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx20.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 119	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx20.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 120	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx20.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 121	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx21.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 122	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx21.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 123	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx21.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 124	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx21.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 125	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx21.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 126	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx21.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 127	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx22.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 128	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx22.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 129	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx22.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 130	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx22.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 131	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx22.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 132	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx22.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 133	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx23.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 134	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx23.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 135	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx23.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 136	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx23.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 137	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx23.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 138	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx23.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 139	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx24.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 140	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx24.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 141	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx24.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 142	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx24.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 143	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx24.raw	1
Sample 1	Homo sapiens	cerebrospinal fluid	1	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 144	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch1_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch1_Fx24.raw	1
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 145	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx01.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 146	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx01.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 147	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx01.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 148	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx01.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 149	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx01.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 150	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx01.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 151	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx02.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 152	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx02.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 153	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx02.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 154	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx02.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 155	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx02.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 156	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx02.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 157	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx03.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 158	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx03.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 159	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx03.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 160	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx03.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 161	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx03.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 162	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx03.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 163	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx04.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 164	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx04.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 165	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx04.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 166	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx04.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 167	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx04.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 168	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx04.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 169	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx05.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 170	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx05.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 171	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx05.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 172	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx05.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 173	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx05.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 174	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx05.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 175	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx06.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 176	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx06.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 177	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx06.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 178	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx06.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 179	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx06.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 180	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx06.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 181	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx07.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 182	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx07.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 183	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx07.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 184	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx07.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 185	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx07.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 186	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx07.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 187	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx08.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 188	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx08.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 189	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx08.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 190	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx08.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 191	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx08.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 192	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx08.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 193	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx09.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 194	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx09.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 195	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx09.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 196	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx09.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 197	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx09.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 198	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx09.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 199	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx10.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 200	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx10.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 201	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx10.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 202	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx10.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 203	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx10.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 204	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx10.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 205	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx11.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 206	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx11.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 207	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx11.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 208	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx11.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 209	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx11.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 210	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx11.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 211	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx12.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 212	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx12.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 213	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx12.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 214	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx12.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 215	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx12.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 216	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx12.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 217	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx13.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 218	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx13.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 219	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx13.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 220	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx13.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 221	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx13.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 222	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx13.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 223	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx14.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 224	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx14.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 225	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx14.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 226	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx14.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 227	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx14.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 228	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx14.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 229	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx15.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 230	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx15.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 231	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx15.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 232	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx15.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 233	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx15.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 234	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx15.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 235	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx16.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 236	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx16.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 237	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx16.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 238	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx16.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 239	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx16.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 240	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx16.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 241	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx17.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 242	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx17.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 243	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx17.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 244	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx17.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 245	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx17.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 246	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx17.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 247	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx18.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 248	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx18.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 249	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx18.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 250	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx18.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 251	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx18.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 252	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx18.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 253	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx19.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 254	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx19.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 255	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx19.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 256	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx19.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 257	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx19.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 258	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx19.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 259	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx20.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 260	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx20.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 261	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx20.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 262	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx20.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 263	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx20.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 264	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx20.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 265	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx21.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 266	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx21.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 267	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx21.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 268	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx21.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 269	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx21.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 270	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx21.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 271	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx22.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 272	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx22.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 273	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx22.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 274	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx22.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 275	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx22.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 276	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx22.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 277	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx23.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 278	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx23.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 279	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx23.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 280	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx23.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 281	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx23.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 282	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx23.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 283	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx24.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 284	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx24.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 285	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx24.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 286	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx24.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 287	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx24.raw	2
Sample 2	Homo sapiens	cerebrospinal fluid	2	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 288	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch2_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch2_Fx24.raw	2
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 289	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx01.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 290	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx01.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 291	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx01.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 292	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx01.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 293	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx01.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 294	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx01.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 295	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx02.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 296	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx02.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 297	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx02.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 298	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx02.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 299	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx02.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 300	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx02.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 301	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx03.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 302	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx03.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 303	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx03.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 304	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx03.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 305	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx03.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 306	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx03.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 307	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx04.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 308	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx04.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 309	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx04.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 310	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx04.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 311	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx04.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 312	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx04.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 313	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx05.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 314	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx05.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 315	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx05.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 316	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx05.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 317	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx05.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 318	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx05.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 319	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx06.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 320	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx06.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 321	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx06.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 322	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx06.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 323	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx06.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 324	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx06.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 325	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx07.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 326	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx07.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 327	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx07.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 328	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx07.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 329	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx07.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 330	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx07.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 331	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx08.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 332	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx08.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 333	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx08.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 334	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx08.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 335	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx08.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 336	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx08.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 337	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx09.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 338	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx09.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 339	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx09.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 340	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx09.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 341	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx09.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 342	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx09.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 343	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx10.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 344	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx10.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 345	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx10.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 346	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx10.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 347	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx10.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 348	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx10.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 349	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx11.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 350	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx11.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 351	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx11.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 352	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx11.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 353	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx11.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 354	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx11.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 355	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx12.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 356	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx12.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 357	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx12.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 358	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx12.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 359	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx12.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 360	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx12.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 361	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx13.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 362	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx13.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 363	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx13.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 364	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx13.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 365	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx13.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 366	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx13.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 367	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 368	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 369	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 370	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 371	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 372	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx14.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 373	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 374	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 375	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 376	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 377	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 378	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx15.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 379	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 380	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 381	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 382	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 383	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 384	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx16.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 385	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 386	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 387	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 388	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 389	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 390	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx17.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 391	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 392	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 393	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 394	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 395	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 396	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx18.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 397	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 398	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 399	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 400	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 401	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 402	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx19.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 403	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx20.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 404	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx20.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 405	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx20.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 406	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx20.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 407	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx20.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 408	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx20.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 409	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx21.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 410	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx21.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 411	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx21.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 412	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx21.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 413	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx21.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 414	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx21.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 415	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx22.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 416	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx22.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 417	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx22.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 418	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx22.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 419	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx22.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 420	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx22.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 421	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx23.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 422	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx23.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 423	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx23.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 424	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx23.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 425	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx23.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 426	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx23.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 427	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx24.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 428	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx24.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient2	tissue	run 429	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx24.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	not available	leptomeningeal melanoma metastases	depletion	Patient7	tissue	run 430	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx24.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 431	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx24.raw	3
Sample 3	Homo sapiens	cerebrospinal fluid	3	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient6	tissue	run 432	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch3_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch3_Fx24.raw	3
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 433	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx01.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 434	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx01.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 435	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx01.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 436	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx01.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 437	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx01.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 438	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx01.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 439	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx02.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 440	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx02.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 441	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx02.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 442	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx02.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 443	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx02.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 444	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx02.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 445	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx03.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 446	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx03.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 447	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx03.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 448	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx03.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 449	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx03.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 450	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx03.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 451	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx04.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 452	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx04.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 453	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx04.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 454	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx04.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 455	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx04.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 456	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx04.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 457	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx05.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 458	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx05.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 459	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx05.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 460	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx05.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 461	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx05.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 462	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx05.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 463	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx06.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 464	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx06.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 465	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx06.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 466	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx06.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 467	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx06.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 468	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx06.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 469	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx07.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 470	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx07.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 471	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx07.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 472	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx07.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 473	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx07.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 474	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx07.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 475	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx08.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 476	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx08.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 477	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx08.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 478	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx08.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 479	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx08.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 480	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx08.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 481	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx09.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 482	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx09.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 483	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx09.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 484	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx09.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 485	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx09.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 486	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx09.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 487	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx10.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 488	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx10.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 489	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx10.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 490	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx10.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 491	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx10.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 492	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx10.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 493	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx11.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 494	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx11.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 495	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx11.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 496	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx11.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 497	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx11.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 498	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx11.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 499	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx12.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 500	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx12.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 501	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx12.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 502	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx12.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 503	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx12.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 504	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx12.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 505	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx13.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 506	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx13.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 507	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx13.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 508	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx13.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 509	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx13.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 510	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx13.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 511	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx14.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 512	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx14.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 513	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx14.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 514	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx14.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 515	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx14.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 516	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx14.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 517	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx15.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 518	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx15.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 519	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx15.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 520	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx15.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 521	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx15.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 522	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx15.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 523	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx16.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 524	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx16.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 525	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx16.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 526	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx16.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 527	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx16.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 528	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx16.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 529	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 530	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 531	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 532	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 533	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 534	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx17.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 535	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 536	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 537	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 538	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 539	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 540	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx18.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 541	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 542	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 543	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 544	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 545	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 546	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx19.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 547	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 548	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 549	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 550	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 551	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 552	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx20.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 553	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 554	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 555	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 556	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 557	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 558	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx21.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 559	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 560	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 561	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 562	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 563	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 564	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx22.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 565	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx23.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 566	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx23.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 567	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx23.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 568	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx23.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 569	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx23.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 570	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx23.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 571	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx24.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 572	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx24.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 573	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx24.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 574	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx24.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 575	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx24.raw	4
Sample 4	Homo sapiens	cerebrospinal fluid	4	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 576	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch4_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch4_Fx24.raw	4
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 577	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx01.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 578	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx01.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 579	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx01.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 580	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx01.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 581	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx01.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 582	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx01.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 583	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx02.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 584	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx02.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 585	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx02.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 586	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx02.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 587	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx02.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 588	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx02.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 589	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx03.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 590	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx03.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 591	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx03.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 592	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx03.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 593	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx03.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 594	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx03.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 595	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx04.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 596	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx04.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 597	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx04.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 598	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx04.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 599	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx04.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 600	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx04.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 601	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx05.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 602	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx05.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 603	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx05.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 604	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx05.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 605	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx05.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 606	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx05.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 607	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx06.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 608	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx06.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 609	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx06.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 610	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx06.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 611	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx06.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 612	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx06.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 613	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx07.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 614	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx07.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 615	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx07.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 616	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx07.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 617	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx07.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 618	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx07.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 619	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx08.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 620	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx08.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 621	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx08.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 622	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx08.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 623	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx08.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 624	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx08.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 625	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx09.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 626	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx09.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 627	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx09.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 628	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx09.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 629	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx09.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 630	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx09.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 631	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx10.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 632	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx10.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 633	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx10.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 634	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx10.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 635	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx10.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 636	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx10.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 637	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx11.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 638	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx11.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 639	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx11.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 640	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx11.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 641	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx11.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 642	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx11.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 643	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx12.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 644	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx12.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 645	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx12.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 646	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx12.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 647	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx12.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 648	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx12.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 649	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx13.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 650	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx13.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 651	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx13.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 652	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx13.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 653	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx13.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 654	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx13.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 655	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx14.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 656	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx14.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 657	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx14.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 658	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx14.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 659	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx14.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 660	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx14.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 661	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx15.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 662	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx15.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 663	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx15.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 664	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx15.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 665	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx15.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 666	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx15.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 667	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx16.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 668	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx16.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 669	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx16.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 670	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx16.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 671	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx16.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 672	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx16.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 673	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx17.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 674	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx17.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 675	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx17.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 676	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx17.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 677	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx17.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 678	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx17.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 679	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx18.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 680	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx18.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 681	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx18.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 682	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx18.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 683	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx18.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 684	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx18.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 685	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx19.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 686	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx19.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 687	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx19.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 688	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx19.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 689	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx19.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 690	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx19.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 691	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx20.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 692	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx20.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 693	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx20.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 694	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx20.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 695	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx20.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 696	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx20.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 697	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx21.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 698	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx21.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 699	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx21.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 700	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx21.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 701	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx21.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 702	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx21.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 703	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx22.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 704	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx22.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 705	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx22.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 706	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx22.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 707	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx22.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 708	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx22.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 709	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx23.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 710	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx23.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 711	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx23.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 712	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx23.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 713	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx23.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 714	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx23.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 715	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx24.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient3	tissue	run 716	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx24.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	female	leptomeningeal melanoma metastases	depletion	Patient1	tissue	run 717	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx24.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 718	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx24.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient4	tissue	run 719	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx24.raw	5
Sample 5	Homo sapiens	cerebrospinal fluid	5	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient9	tissue	run 720	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch5_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch5_Fx24.raw	5
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 721	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx01.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 722	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx01.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 723	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx01.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 724	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx01.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 725	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx01.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 726	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx01.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 727	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx02.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 728	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx02.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 729	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx02.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 730	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx02.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 731	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx02.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 732	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx02.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 733	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx03.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 734	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx03.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 735	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx03.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 736	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx03.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 737	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx03.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 738	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx03.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 739	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx04.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 740	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx04.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 741	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx04.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 742	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx04.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 743	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx04.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 744	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx04.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 745	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx05.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 746	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx05.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 747	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx05.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 748	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx05.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 749	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx05.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 750	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx05.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 751	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx06.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 752	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx06.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 753	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx06.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 754	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx06.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 755	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx06.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 756	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx06.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 757	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx07.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 758	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx07.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 759	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx07.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 760	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx07.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 761	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx07.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 762	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx07.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 763	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx08.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 764	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx08.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 765	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx08.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 766	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx08.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 767	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx08.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 768	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx08.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 769	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx09.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 770	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx09.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 771	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx09.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 772	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx09.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 773	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx09.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 774	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx09.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 775	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx10.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 776	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx10.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 777	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx10.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 778	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx10.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 779	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx10.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 780	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx10.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 781	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx11.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 782	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx11.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 783	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx11.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 784	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx11.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 785	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx11.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 786	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx11.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 787	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx12.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 788	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx12.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 789	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx12.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 790	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx12.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 791	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx12.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 792	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx12.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 793	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx13.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 794	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx13.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 795	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx13.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 796	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx13.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 797	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx13.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 798	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx13.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 799	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx14.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 800	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx14.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 801	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx14.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 802	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx14.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 803	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx14.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 804	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx14.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 805	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx15.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 806	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx15.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 807	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx15.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 808	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx15.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 809	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx15.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 810	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx15.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 811	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx16.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 812	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx16.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 813	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx16.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 814	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx16.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 815	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx16.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 816	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx16.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 817	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx17.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 818	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx17.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 819	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx17.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 820	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx17.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 821	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx17.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 822	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx17.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 823	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx18.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 824	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx18.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 825	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx18.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 826	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx18.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 827	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx18.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 828	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx18.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 829	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx19.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 830	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx19.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 831	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx19.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 832	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx19.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 833	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx19.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 834	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx19.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 835	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx20.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 836	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx20.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 837	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx20.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 838	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx20.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 839	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx20.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 840	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx20.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 841	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx21.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 842	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx21.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 843	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx21.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 844	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx21.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 845	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx21.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 846	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx21.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 847	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx22.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 848	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx22.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 849	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx22.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 850	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx22.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 851	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx22.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 852	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx22.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 853	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx23.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 854	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx23.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 855	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx23.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 856	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx23.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 857	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx23.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 858	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx23.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 859	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx24.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 860	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx24.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 861	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx24.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 862	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx24.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 863	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx24.raw	6
Sample 6	Homo sapiens	cerebrospinal fluid	6	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient5	tissue	run 864	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch6_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch6_Fx24.raw	6
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 865	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx01.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 866	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx01.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 867	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx01.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 868	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx01.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 869	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx01.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 870	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	1	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx01.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx01.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 871	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx02.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 872	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx02.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 873	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx02.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 874	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx02.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 875	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx02.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 876	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	2	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx02.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx02.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 877	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx03.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 878	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx03.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 879	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx03.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 880	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx03.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 881	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx03.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 882	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	3	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx03.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx03.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 883	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx04.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 884	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx04.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 885	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx04.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 886	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx04.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 887	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx04.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 888	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	4	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx04.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx04.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 889	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx05.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 890	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx05.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 891	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx05.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 892	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx05.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 893	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx05.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 894	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	5	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx05.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx05.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 895	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx06.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 896	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx06.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 897	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx06.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 898	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx06.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 899	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx06.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 900	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	6	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx06.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx06.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 901	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx07.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 902	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx07.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 903	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx07.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 904	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx07.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 905	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx07.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 906	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	7	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx07.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx07.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 907	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx08.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 908	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx08.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 909	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx08.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 910	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx08.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 911	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx08.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 912	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	8	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx08.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx08.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 913	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx09.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 914	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx09.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 915	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx09.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 916	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx09.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 917	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx09.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 918	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	9	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx09.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx09.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 919	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx10.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 920	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx10.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 921	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx10.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 922	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx10.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 923	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx10.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 924	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	10	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx10.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx10.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 925	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx11.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 926	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx11.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 927	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx11.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 928	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx11.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 929	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx11.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 930	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	11	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx11.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx11.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 931	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx12.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 932	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx12.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 933	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx12.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 934	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx12.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 935	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx12.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 936	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	12	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx12.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx12.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 937	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx13.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 938	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx13.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 939	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx13.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 940	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx13.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 941	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx13.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 942	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	13	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx13.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx13.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 943	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx14.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 944	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx14.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 945	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx14.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 946	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx14.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 947	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx14.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 948	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	14	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx14.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx14.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 949	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx15.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 950	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx15.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 951	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx15.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 952	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx15.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 953	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx15.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 954	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	15	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx15.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx15.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 955	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx16.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 956	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx16.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 957	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx16.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 958	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx16.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 959	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx16.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 960	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	16	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx16.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx16.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 961	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx17.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 962	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx17.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 963	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx17.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 964	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx17.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 965	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx17.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 966	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	17	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx17.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx17.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 967	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx18.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 968	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx18.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 969	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx18.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 970	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx18.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 971	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx18.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 972	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	18	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx18.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx18.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 973	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx19.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 974	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx19.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 975	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx19.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 976	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx19.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 977	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx19.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 978	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	19	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx19.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx19.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 979	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx20.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 980	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx20.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 981	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx20.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 982	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx20.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 983	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx20.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 984	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	20	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx20.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx20.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 985	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx21.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 986	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx21.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 987	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx21.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 988	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx21.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 989	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx21.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 990	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	21	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx21.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx21.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 991	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx22.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 992	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx22.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 993	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx22.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 994	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx22.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 995	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx22.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 996	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	22	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx22.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx22.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 997	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx23.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 998	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx23.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 999	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx23.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1000	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx23.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1001	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx23.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1002	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	23	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx23.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx23.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	not applicable	normal	depletion	Pool	tissue	run 1003	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT126	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx24.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1004	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT127	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx24.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1005	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT128	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx24.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1006	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT129	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx24.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1007	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT130	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx24.raw	7
Sample 7	Homo sapiens	cerebrospinal fluid	7	not available	not available	not available	not applicable	not applicable	male	leptomeningeal melanoma metastases	depletion	Patient8	tissue	run 1008	proteomic profiling by mass spectrometry	NT=Reversed-phase chromatography (RP);AC=PRIDE:0000563	24	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/01/PXD016002/20171207_Inna-CSF_TMTBatch7_Fx24.raw	NT=Q Exactive Plus;AC=MS:1002634	AC=PRIDE:0000563;NT=Reversed-phase chromatography	TMT131	AC=MS:1001251;NT=Trypsin	not available	not available	not available	not available	20171207_Inna-CSF_TMTBatch7_Fx24.raw	7
